InflaRx NV IFRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IFRX is a good fit for your portfolio.
News
-
InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event
-
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans
-
InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024
-
InflaRx Appoints Jan Medina as Head of Investor Relations
-
InflaRx Shares Soar 40% on FDA Emergency Use Authorization of Gohibic for Covid-19
-
InflaRx's Gohibic Gets Emergency Use Authorization from FDA for Covid-19 Hospitalized Patients
Trading Information
- Previous Close Price
- $1.39
- Day Range
- $1.28–1.43
- 52-Week Range
- $1.14–5.20
- Bid/Ask
- $1.25 / $1.45
- Market Cap
- $78.31 Mil
- Volume/Avg
- 169,301 / 238,191
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1,070.66
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 66
- Website
- https://www.inflarx.de
Comparables
Valuation
|
Metric
|
IFRX
|
MRUS
|
VVY
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.69 | 7.29 | 0.56 |
Price/Sales | 1,070.66 | 52.76 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
IFRX
|
MRUS
|
VVY
|
|---|---|---|---|
Quick Ratio | 5.58 | 5.19 | 18.38 |
Current Ratio | 6.50 | 5.34 | 19.45 |
Interest Coverage | −1,303.38 | — | −104.42 |
Quick Ratio
IFRX
MRUS
VVY
Profitability
|
Metric
|
IFRX
|
MRUS
|
VVY
|
|---|---|---|---|
Return on Assets (Normalized) | −33.99% | −30.87% | −61.97% |
Return on Equity (Normalized) | −37.92% | −42.51% | −72.07% |
Return on Invested Capital (Normalized) | −41.11% | −44.25% | −68.80% |
Return on Assets
IFRX
MRUS
VVY
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Vvbpcqxd | Rzhhv | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xxfhxmrds | Xpnhcks | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Sjcxywdw | Brxfwyn | $97.8 Bil | |
MRNA
| Moderna Inc | Vqsgpkrg | Ysjzh | $41.3 Bil | |
ARGX
| argenx SE ADR | Llpszvsz | Lspjd | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Mqndbgqt | Wvky | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Whwmzzj | Zvnrdn | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Qlynqjf | Fgphgf | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Prgscmkbk | Vwkrm | $12.5 Bil | |
INCY
| Incyte Corp | Gpcksmzn | Rnyjnk | $11.6 Bil |